Trials / Not Yet Recruiting
Not Yet RecruitingNCT07445906
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
A Phase I Clinical Study to Evaluate the Safety, Tolerability, PK and PD of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous injection of RG002C0106 between trial participants with normal renal function and those with mild to moderate renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RG002C0106 | Subcutaneous (SC) single dose 200mg |
Timeline
- Start date
- 2026-03-15
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2026-03-03
- Last updated
- 2026-03-03
Source: ClinicalTrials.gov record NCT07445906. Inclusion in this directory is not an endorsement.